AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
36.36
-0.22 (-0.60%)
Nov 3, 2025, 10:21 AM EST - Market open
AnaptysBio Revenue
AnaptysBio had revenue of $22.26M in the quarter ending June 30, 2025, with 102.93% growth. This brings the company's revenue in the last twelve months to $123.16M, up 304.17% year-over-year. In the year 2024, AnaptysBio had annual revenue of $91.28M with 432.03% growth.
Revenue (ttm)
$123.16M
Revenue Growth
+304.17%
P/S Ratio
8.82
Revenue / Employee
$905,618
Employees
136
Market Cap
1.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
ANAB News
- 5 days ago - Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation - GlobeNewsWire
- 19 days ago - AnaptysBio, Inc. - Special Call - Seeking Alpha
- 21 days ago - Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 - GlobeNewsWire
- 4 weeks ago - AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Benzinga
- 4 weeks ago - Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 - GlobeNewsWire
- 4 weeks ago - Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 - GlobeNewsWire
- 2 months ago - Anaptys Announces Participation in September Investor Conferences - GlobeNewsWire
- 3 months ago - Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire